烧伤患者细胞色素P450多态性与芬太尼药代动力学的初步研究
本研究对13例烧伤面积大于20%TBSA的患者进行芬太尼药代动力学分析与CYP基因分型,发现3例携带CYP2D6*9、CYP2D6*29或CYP3A4*1B慢代谢基因型的患者因清除受损而血药浓度升高,提示需进一步研究个体化基因分型指导阿片类药物镇痛。
要点
- 烧伤高代谢与CYP基因多态性可致芬太尼药代动力学个体差异。
- CYP2D6*9、CYP2D6*29和CYP3A4*1B慢代谢型患者芬太尼清除受损、血药浓度升高。
- 建议进一步研究以支持个体化CYP基因分型指导阿片类药物精准镇痛。
核心结论
- 携带CYP2D6*9、CYP2D6*29或CYP3A4*1B慢代谢基因型的烧伤患者芬太尼清除受损、血药浓度升高。
- 本初步研究支持在阿片类镇痛前进行CYP基因分型以指导精准决策、提高疗效与安全性。
研究设计与样本
- 初步研究,利用既往库存血样,纳入13例烧伤面积大于20%TBSA的患者(8男5女)。
- 患者平均(SD)年龄41.7(14.5)岁,平均烧伤面积25.8(15.3)%TBSA。
- 测定血浆芬太尼浓度并进行CYP基因分型,采用Monolix软件以二室群体模型进行药代动力学分析。
主要发现
- 鉴定出3种CYP慢代谢基因型:CYP2D6*9、CYP2D6*29和CYP3A4*1B。
- 全部3例携带变异多态性的患者均因清除受损而血清芬太尼浓度升高。
临床怎么用
- 烧伤患者镇痛时需考虑CYP基因多态性对芬太尼药代动力学的影响。
- 对携带CYP2D6*9、CYP2D6*29或CYP3A4*1B慢代谢型患者应警惕芬太尼清除受损导致的血药浓度升高。
局限性
- 本研究为初步研究,样本量仅13例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pain management is critical for burn care. Unfortunately, interindividual variation in pharmacokinetics (PK) due to burn hypermetabolism and genetic polymorphisms can lead to treatment failures in this at-risk population. Analgesics may be affected by genetic polymorphisms affecting cytochrome P450 (CYP) drug metabolizing enzymes. Fentanyl is a common opiate primarily metabolized by CYP3A4 subtypes. Recent studies demonstrate CYP2D6 variants, affecting fentanyl PK. Functional CYP polymorphisms can significantly alter opiate levels resulting in inadequate analgesia or life-threatening toxicity. The goal of our study was to evaluate fentanyl PK and assess associations with CYP polymorphisms. We obtained samples from the previously banked blood of 13 patients (eight males and five females) with >20% TBSA burns. Mean (SD) patient age was 41.7 (14.5) years, and mean burn size was 25.8 (15.3) %TBSA. Plasma fentanyl was quantified, and CYP genotyping was performed. Pharmacokinetic analysis was performed using Monolix software (Lixsoft, France) with a two-compartment population model best-representing fentanyl profiles. Three CYP slow-metabolizing genotypes were identified, which included CYP2D6*9, CYP2D6*29, and CYP3A4*1B. All three patients with variant polymorphisms had increased serum fentanyl concentrations due to impaired clearance. This pilot study supports the need for further research in this topic, and CYP genotyping of individual patients prior to receiving opiate analgesics to inform precision-guided decisions, improve therapeutic efficacy, and, most importantly, increase patient well-being and safety.
引用
- Grimsrud KN, Ivanova X, Sherwin CM, et al. Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study. J Burn Care Res. 2019. PMID: 30371861. doi:10.1093/jbcr/iry053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。